What Is African Swine Fever?
African Swine Fever (ASF) is a highly contagious viral disease that affects only pigs and wild boars. It is caused by the African swine fever virus (ASFV), a large double-stranded DNA virus belonging to the Asfarviridae family. The disease causes high fever, internal bleeding, and lesions in affected animals, with mortality often reaching 100% in domestic pigs.
The virus does not infect humans, so ASF is a non-zoonotic disease and poses no direct threat to public health. It should not be confused with swine flu (H1N1), which is a respiratory infection that can spread from pigs to humans. The danger from ASF is entirely economic and social: it destroys pig herds, collapses rural livelihoods, and disrupts meat supply chains.
First identified in Kenya in 1921, ASF historically remained confined to Africa, where warthogs and bushpigs act as silent carriers. The virus escaped the continent in 2007 when it appeared in the country of Georgia, and from there it spread across Europe and into Asia. China, the world’s largest pork producer, lost more than half of its pig population to the 2018 outbreak, sending pork prices soaring worldwide.
Analogy · Why ASF Spreads So Fast Expand analogy
Think of ASF as a fire that no fire extinguisher works on. Once a pig is infected, there is no cure, so the only option left is to demolish the building around it, meaning culling every pig on the farm and nearby. That is why controlling ASF without a vaccine is so punishing for farmers.
Why ASF Is Difficult to Control
ASF is notoriously hard to contain for several reasons. The virus is extremely hardy in the environment: it can survive for months in contaminated feed, on farm equipment, in the soil, and even in frozen or processed pork products such as sausages and ham. It takes heating at 70°C for 30 minutes to destroy the virus in meat.
The disease spreads through direct contact between infected and healthy pigs, through contaminated objects, feed, and clothing, and through the bites of soft ticks of the genus Ornithodoros, which act as biological vectors and can carry the virus for years. Because there is no treatment and no cure, containment has historically relied on rapid diagnosis, the culling of infected and exposed animals, strict movement restrictions, and biosecurity measures such as disinfecting vehicles, boots, and equipment.
A further complication is that infected animals can shed the virus before showing any symptoms, so the disease often travels silently across borders. Its long survival in pork products also means that the illegal movement of meat, rather than live animals, frequently carries the virus into new countries. This combination of hardiness, silent spread, and absence of a cure made vaccine development the single most important line of defence.
The Breakthrough: India’s First Indigenous ASF Vaccine
The new vaccine, named MA-104 after the cell line used to produce it, is a live attenuated vaccine. This means it uses a version of the African swine fever virus that has been weakened, or attenuated, so that it triggers an immune response in pigs without causing the disease itself.
How the Vaccine Was Developed
Scientists at ICAR-NIHSAD, Bhopal, developed the vaccine from a novel attenuated ASFV Genotype II virus with unique gene deletions. The starting point was an Indian field isolate of the virus, meaning a strain collected from actual outbreaks in the country. Genotype II is the same dominant strain behind major outbreaks in Asia and Europe since 2018.
The key innovation lies in the MA-104 cell line, a commercially available culture of kidney epithelial cells derived from the African green monkey. Using a widely available cell line allows the vaccine to be produced in large volumes at low cost, without relying on the patented proprietary cell lines that global competitors use. This makes the vaccine well suited for large-scale domestic production.
The vaccine underwent comprehensive laboratory evaluation covering sterility, purity, safety, genetic stability, immunogenicity, protective efficacy, and reversion to virulence studies. Reversion to virulence is the risk that a weakened vaccine virus might regain its disease-causing strength, and no such risk was found. The vaccine was then field validated in collaboration with the Department of Animal Husbandry and Dairying (DAHD), confirming its safety and effectiveness under real-world farm conditions.
Dosage and Administration
The vaccine is recommended for healthy pigs above eight weeks of age. It is administered as a single 1 mL intramuscular injection, typically in the neck muscles, followed by a booster dose 14 days after the primary shot. Trials showed the vaccine provides strong immunity lasting up to six months.
ASF’s Toll on India’s Pig Economy
India has a pig population of roughly 9 million, of which about 45% is concentrated in the northeastern states. For tribal and smallholder communities in the Northeast, pig rearing is not just an income source but a part of daily life, with pork serving as a staple food and pigs playing a role in cultural and ceremonial practices.
ASF was first confirmed in India in 2020, in outbreaks reported in Arunachal Pradesh and Assam. It has since spread across several states and union territories, causing massive pig mortality, disruption of pig production, restrictions on animal movement and trade, and severe losses for smallholder farmers.
The financial damage has been enormous. The initial outbreaks in Assam in 2020 and 2021 caused estimated losses of about ₹276 crore due to pig deaths and culling. In Mizoram, ASF outbreaks affected more than 11,382 households by 2025, with financial losses estimated at nearly ₹982 crore. These figures explain why an affordable indigenous vaccine is seen as a lifeline for millions of pig farmers, and why the government described the development as a major step towards strengthening livestock biosecurity and reducing dependence on imported veterinary technology.
A Rare Club: India Among Few Countries with ASF Vaccines
Only a handful of commercially licensed ASF vaccines exist anywhere in the world. Vietnam became the first country to commercialise them in 2023, when it approved two live attenuated vaccines developed from the pandemic Georgia strain of the virus, one known as NAVET-ASFVAC and the other as AVAC ASF LIVE.
Those vaccines rely on patented proprietary cell lines, which limits who can manufacture them. India’s MA-104 vaccine is different because it uses the readily available MA-104 cell line, making it a genuine technological breakthrough and a cost-effective, scalable alternative to foreign platforms. This positions India among the very few countries with indigenous ASF vaccine capability, and opens the possibility of exporting an affordable vaccine to other countries in Asia and Africa that are struggling with the disease.
The Institutions Behind the Breakthrough
ICAR-NIHSAD, Bhopal
The National Institute of High Security Animal Diseases (NIHSAD) is a premier ICAR institute located in Bhopal, Madhya Pradesh, dedicated to research on exotic and emerging pathogens of animals. It traces its origins to the High Security Animal Disease Laboratory (HSADL), which was established in 1987 with technical collaboration from the UNDP and the FAO, and was renamed NIHSAD in 2014.
NIHSAD is India’s only institute with high biocontainment laboratories (BSL-3 and BSL-4) for handling dangerous animal pathogens. It serves as the national repository for rinderpest virus material and is a WOAH reference laboratory for avian influenza. The institute has processed more than 13 lakh samples from domestic livestock and poultry. The ASF vaccine was developed by a team including Dr. D. Senthil Kumar, Dr. K. Rajukumar, Dr. G. Venkatesh, and Dr. Fateh Singh, led by the institute’s director, Dr. Aniket Sanyal.
Indian Council of Agricultural Research (ICAR)
The Indian Council of Agricultural Research (ICAR) is an autonomous body established on 16 July 1929 as the Imperial Council of Agricultural Research, following the recommendations of the Royal Commission on Agriculture. It operates under the Department of Agricultural Research and Education (DARE) in the Ministry of Agriculture and Farmers Welfare and is headquartered in New Delhi.
ICAR is the apex body coordinating agricultural research and education in India, overseeing 113 institutes and 74 agricultural universities. It played a pioneering role in the Green Revolution. The vaccine was dedicated to the nation on 16 July 2026, the date of the 98th Foundation Day, at the NASC Complex in New Delhi, in the presence of Union Agriculture Minister Shivraj Singh Chouhan and Union Minister for Fisheries, Animal Husbandry and Dairying Rajiv Ranjan Singh.
The Way Forward
The next step is to take the vaccine from the laboratory to the market. This involves patenting, auctioning the technology to a pharmaceutical company, and large-scale manufacturing, with the vaccine expected to be commercially available within about six months. Once in production, the priority will be vaccination campaigns targeting pig-rearing states, especially in the Northeast.
Beyond disease control, the vaccine carries a wider strategic significance. It advances the goals of Atmanirbhar Bharat and Make in India by cutting dependence on imported veterinary products, and it positions India to emerge as a global supplier of affordable veterinary vaccines.
Key Takeaways
- MA-104 is India’s first indigenous live attenuated vaccine against African Swine Fever, developed by ICAR-NIHSAD, Bhopal.
- ASF is a highly contagious viral disease of pigs and wild boars caused by the African swine fever virus, a DNA virus of the Asfarviridae family, with a mortality rate of nearly 100%.
- The vaccine was dedicated to the nation on 16 July 2026 during the 98th Foundation Day of ICAR at the NASC Complex, New Delhi.
- The vaccine uses a novel attenuated ASFV Genotype II virus cultured in the widely available MA-104 cell line, enabling low-cost, large-scale production without proprietary platforms.
- It is recommended for healthy pigs above eight weeks of age as a 1 mL intramuscular injection, followed by a booster dose after 14 days.
- ASF was first detected in India in 2020, and outbreaks caused estimated losses of ₹276 crore in Assam (2020-21) and about ₹982 crore in Mizoram by 2025.
- ICAR-NIHSAD, India’s only institute with BSL-3 and BSL-4 high-containment animal disease laboratories, traces its origin to the High Security Animal Disease Laboratory established in 1987.
- ICAR, the apex body for agricultural research, was established on 16 July 1929 and functions under the Department of Agricultural Research and Education (DARE).
